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ABSTRACT 
Purpose:  
The abstinence rate to tobacco after varenicline treatment is moderate and might be partially affected 
by variability in varenicline concentrations. This study aimed at characterizing the sources of variability 
in varenicline pharmacokinetics and to relate varenicline exposure to abstinence.  
Methods:   
The population pharmacokinetic analysis (NONMEM®) included 121 varenicline concentrations from 
82 individuals and tested the influence of genetic and non-genetic characteristics on apparent 
clearance (CL/F) and volume of distribution (V/F). Model-based average concentrations over 24 h (Cav) 
were used to test the impact of varenicline exposure on the input rate (Kin) expressed as a function of 
the number of cigarettes per day in a turnover model of 373 expired carbon monoxide levels. 
Results:  
A one-compartment model with first order absorption and elimination appropriately described 
varenicline concentrations. CL/F was 8.5 L/h (coefficient of variation, 26%), V/F was 228 L and the 
absorption rate (ka) was fixed to 0.98 h-1. CL/F increased by 46% in 100-kg individuals compared to 60-
kg individuals and was found to be 21% higher in UGT2B7 rs7439366 TT individuals. These covariates 
explained 14% and 9% of the inter-individual variability in CL/F, respectively. No influence of 
varenicline Cav was found on Kin in addition to the number of cigarettes.  
Conclusions:  
Body weight mostly and to a smaller extent genetic polymorphisms of UGT2B7 can influence 
varenicline exposure. Dose adjustment based on body weight and, if available, on UGT2B7 genotype 
might be useful to improve clinical efficacy and tolerability of varenicline. 
 
 
Keywords: varenicline, pharmacokinetics, pharmacogenetics, dose individualization, variability 
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INTRODUCTION 
Varenicline, a selective partial agonist of the α4β2 nicotinic acetylcholine receptor, indicated as an aid 
to smoking cessation, has a moderate efficacy on smoking abstinence at best. In more than 160,000 
treatment episodes of smokers from smoking cessation clinic, the reported 4-week success rate was 
44% [1]. The continuous abstinence rate was 44% during the treatment period of week 9 to 12 and 
decreased to 30% between the week 9 to 24 in a randomized trial including 1000 smokers [2]. Based 
on dose-ranging studies, the manufacturer established an exposure-response relationship 
characterized by an increase of the probability of continuous abstinence during the treatment period 
from the week 9 to 12 (9-12 CAR) with increasing varenicline exposure. The probability of 9-12 CAR 
was estimated from 0.3 to 0.7 over the range of varenicline AUC0-24,SS from 60 to 450 ng.h/mL in 
individuals receiving the recommended dose 1 mg b.i.d. [3].  
The drug is mainly eliminated in the form of the unchanged molecule (>90%) and in two 
pharmacologically inactive metabolites (<10%) of which one is obtained by glucuronidation via the 
UDP-glucuronosyltransferase 2B7 isoform (UGT2B7)  [4,5]. Varenicline is excreted unchanged in urine 
mainly via glomerular filtration but active tubular secretion also occurs trough organic cation 
transporter 2 (OCT2) [5] . A variety of genetic polymorphisms of the SLC22A2 gene coding for the OCT2 
transporter and of the UGT2B7 gene might have an influence on varenicline exposure. Expression of 
the genes coding for phase I and phase II drug-metabolizing enzymes and transporters, such as UGT2B7 
and OCT2 are regulated by transcription factors such as: the constitutive androstane receptor (CAR, 
encoded by the NR1|3 gene), the pregnane X receptor (PXR, encoded by the NR1|2 gene), the estrogen 
receptor 1 (encoded by the ESR1 gene), the farnesoid X receptor (FXR, encoded by the NR1H4 gene), 
the peroxisome proliferator activated receptor gamma (PPARγ encoded by the NR1C2 gene) and its 
coactivator PPAR coactivator 1-alpha (PPARGC1A) which all have genetic polymorphisms [6-14]. 
Finally, genetic variability in the α4β2 nicotinic acetylcholine receptor (CHRNA4 gene) where varenicline 
binds might also explain variability in the effectiveness of the drug. To date, a published population 
pharmacokinetic analysis of varenicline showed the influence of demographic and clinical variation on 
drug exposure but genetic characteristics were not studied [15].  
The objectives of this study were to develop a population pharmacokinetic model to assess the 
influence of clinical and genetics factors on varenicline exposure, and to further explore the 
relationships between varenicline blood levels and treatment success measured by the expired carbon 
monoxide (CO) during a 3-month treatment period. 
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MATERIALS AND METHODS 
Study population and design 
Smokers from the general population wishing to participate in a smoking cessation program were 
recruited in the clinical and pharmacogenetic study. Details on the study population, inclusion and 
exclusion criteria and on the smoking cessation program are provided in the Supplemental material 1. 
Among the 194 smokers included in the study, 95 subjects chose to receive varenicline. Two blood 
samplings performed at the beginning and after one month of treatment were used to determine 
varenicline and cotinine plasma concentrations. Cotinine is the major metabolite of nicotine with a 
half-life of 16-17 hours. Subjects are biochemically confirmed abstinent from smoking if plasma 
cotinine ≤ 15 ng/mL [16-18]. At each visit, abstinence from smoking was assessed by self-declaration 
and by expired CO levels (Micro Smokerlyzer; Bedfont Scientific, Rochester, England) lower than 10 
ppm [18,19]. Smoking withdrawal symptoms were also recorded by a self-administered questionnaire 
[20]. Each symptom was assessed by 3 or 4 questions and summarized with a score from a minimal to 
a maximal grade as follow: depression (min: 4 - max: 20), craving (4-20), irritation (4-20), concentration 
(3-15), appetite and weight gain (3-15), and insomnia (3-15). Co-medications were also registered. The 
study was approved by the Ethics Committee of the Lausanne University Medical School and by the 
Swiss Agency for Therapeutic Products (Swissmedic, Bern, Switzerland). Written informed consent was 
obtained from all participants.  
 
Varenicline and cotinine concentration measurements 
Briefly, all blood samples were collected in EDTA-containing tubes. After centrifugation, plasma 
samples were stored at -20°C until analysis. Varenicline and cotinine plasma concentrations were 
determined by ultra performance liquid chromatography coupled with tandem mass spectrometry as 
previously described [21]. Details of the analytical procedure are provided in the Supplemental 
material 1. 
 
Genotyping  
Genomic DNA was extracted from EDTA blood sample at the baseline visit using the FlexiGene DNA 
extraction kit (Qiagen Instruments AG, Hombrechtikon, Switzerland) according to the manufacturer’s 
protocol. The following SNPs were selected based on previously published pharmacogenetic studies 
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and on their minor allele frequency (MAF) in the Caucasian population [22,23,7,8,24-36]: SLC22A2 
(rs316003), SLC22A2 (rs316019), SLC22A2 (rs2279463), UGT2B7 802T>C (rs7439366), NR1|2 
(rs1523130), NR1|2 (rs2472677), NR1|2 (rs7643645), NR1|3 (rs2307424), NR1|3 (rs4073054), NR1|3 
(rs2502815), RXRA (rs3132297), RXRA (rs3818740), PPARG (rs3856806), PPARG (rs1801282), 
PPARGC1A (rs8192678), ESR1 (rs6902771), ESR1 (rs9322336), FXR (rs4764980), HNF1 (rs1169288), 
CHRNA4 (rs1044396). GenomeStudio Data Analysis Software was used to export results generated by 
Illumina Cardio-MetaboChip. Details on genotyping are provided in the Supplemental material 1.  
 
Pharmacokinetic-pharmacodynamic analysis 
Non-linear mixed effect modelling was performed using NONMEM® version 7.3 program [37] with the 
PsN-Toolkit (version 3.2.4) [38]. 
 
Base model 
A stepwise procedure was used to identify models that best fitted the data. Multi-compartment 
models with linear elimination were first fitted to the data to determine the appropriate structural 
model, which was finally identified as a one-compartment model. Since varenicline was administered 
orally, apparent clearance (CL/F) and volume of distribution (V/F) were estimated (where F is the 
absolute oral bioavailability). Exponential errors following a log-normal distribution were assumed for 
the description of inter-individual variability of the parameters. Proportional, additive and combined 
proportional-additive error models were finally compared to describe the residual variability. 
 
Exposure-response analysis 
Average varenicline concentration over 24 hours (Cav) at each visit day assuming a complete 
adherence to treatment were derived using:  
Cav = AUC0-24/24 (1) 
where AUC0-24 were computed analytically in NONMEM® based on the individual dose history and 
pharmacokinetic parameters. 
Only data from visits during the period of effective dose (1 mg twice daily) were included. Whenever 
a cotinine measurement was available, cotinine and CO levels were compared based on the definition 
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of abstinence (≤ 15 ng/mL and < 10 ppm, respectively). If they were discordant, data of the visit were 
excluded from further analyses.  
CO observations were used as a clinical marker of response to varenicline and were described by an 
indirect response model using the following equations describing a basal turnover:  
 
dCO/dt = Kin – Kout * CO 
initial condition: CO(0) = Kin / Kout (2) 
 
Kin = A + EFFCPD * CPD  (3) 
 
where Kin is a zero order input rate and Kout a first-order degradation rate. The effect (EFFCPD) of the 
number of cigarettes per day (CPD) on Kin was directly integrated in the model as a surrogate marker 
of varenicline therapy. Finally, A represents the contribution of all other sources of CO production 
(environmental sources and endogenous metabolism) to Kin [39].  
 
Covariate analysis 
Bayesian estimates of the pharmacokinetic parameters were derived and plotted against the available 
subject characteristics (body weight (BW), age, ethnicity, sex, height, glomerular filtration rate (GFR) 
estimated with the Modification of Diet in Renal Disease (MDRD) formula [40], smoking status, co-
medications and several genetic polymorphisms (see Table 1)). Potentially influencing covariates were 
then incorporated sequentially in the model and tested for significance on the pharmacokinetic 
parameters. The covariate analysis was performed using a stepwise insertion/deletion approach 
testing linear or non-linear functions as appropriate (categorical covariates coded as 0 and 1, 
continuous covariates centered on their median value). Parameter values were estimated for each 
genotypic group (rich model), defined as the reference allele group (Ref) and alternative allele groups: 
heterozygote alternative (Het-Alt) and homozygous alternative (Hom-Alt) or for further regrouped 
(reduced model) subpopulations.  
In the exposure-response analysis, several covariates (continuous: Cav, nicotine metabolite ratio, i.e. 
3-hydroxycotinine/cotinine ratio during smoking ad libitum, BW, age, study duration and recorded 
scores of smoking withdrawal symptoms; categorical: sex, UGT2B7 802T>C (rs7439366) and CHRNA4 
(rs1044396) polymorphisms) were tested on EFFCPD. Influence of sex, age and BW on A parameter 
was also investigated.  
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Parameter estimation and model selection 
The log likelihood ratio test, based on changes in the objective function value (ΔOFV) was employed 
to discriminate between hierarchical models. Since a ΔOFV between any two models approximates a 
χ2 distribution, a 3.8- (p=0.05) and 6.4- (p=0.01) point change of OFV was considered statistically 
significant for one additional parameter in model building and backward deletion steps, respectively. 
The Akaike’s information criterion (AIC) was instead employed to choose between non-hierarchical 
models. Diagnostic goodness-of-fit plots, precision and plausibility of the model parameters were also 
used to assess the reliability of the results. Details on estimation method are provided in the 
Supplemental material 1. 
 
Model evaluation and simulation  
For pharmacokinetic and exposure-response analyses, the final model stability was assessed by 
medians of the non-parametric bootstrap method implemented in PsN [38], generating 2000 datasets 
by re-sampling from the original dataset. Median parameters values with their 95%CI were thus 
derived and compared with the final model estimates. The predictive performance of the 
pharmacokinetic models was evaluated by calculation of the normalized prediction distribution errors 
(NPDEs) [41]. Visual predictive check (VPC) was finally performed with NONMEM® by simulations based 
on the final pharmacokinetic model with interpatient variability using 1000 UGT2B7 TC (Het-Alt) or CC 
(Hom-Alt) individuals of 77 kg (median population BW) to calculate the average concentration time 
profile with 95% prediction intervals (95%PI).  
The trough concentrations at steady-state (CminSS) after administration of 1 mg b.i.d were calculated 
based on the final model in 500 individuals per strata of UGT2B7 rs7439366 genotypes and BW values 
and then plotted with the trough concentrations range expected for the recommended dose of 1 mg 
b.i.d (4-5 ng/mL) reported in the clinical trials supporting the development of varenicline for 
comparison [42]. Figures were generated with GraphPad Prism® (Version 5.00 for Windows, GraphPad 
Software, San Diego California USA, http://www.graphpad.com/) and with R (v. 3.1.2, http://www.r-
project.org). 
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RESULTS 
Study population and data  
Among the 95 subjects enrolled in the study and receiving varenicline, 8 subjects had early treatment 
discontinuation and 5 subjects had no detectable varenicline levels suggesting a poor treatment 
adherence. The remaining 82 subjects provided a total of 121 concentrations for the pharmacokinetic 
analysis: 70 samples were collected at treatment initiation (from days 1 to 10) and 51 samples were 
collected after one month of treatment (from days 35 to 88). Subject’s characteristics are presented 
in Table 1. For the exposure-response analysis, a total of 373 CO measurements from 76 patients were 
available (median= 2 ppm, range= 0-45 ppm). Details on data are provided in the Supplemental 
material 1.  
 
Pharmacokinetic-pharmacodynamic analysis 
Pharmacokinetic analysis 
A one-compartment model with first-order absorption and elimination described adequately the data. 
No improvement to the fit was observed using a two-compartment model (ΔOFV = -0.3). Owing to very 
limited measurements at early time points after drug intake, the absorption parameter ka could not be 
estimated and was thus fixed to 0.98 h-1 to achieve a peak concentration 3-4 hours after drug intake 
as reported in literature [15]. The association of an inter-individual variability to V/F or ka in addition 
to CL/F did not improve the model fit (ΔOFV ≥ -0.3). Finally, residual variability was described by a 
proportional error model. The estimates of the base pharmacokinetic model were a CL/F of 9.6 L/h 
and a V/F of 211 L. The inter-individual variability for CL/F was 26% with a shrinkage of 22% which is 
not misleading for covariate analysis [43]. 
Univariate analyses showed that the effect of BW (ΔOFV = -14.5, p<0.001), height (ΔOFV = -11.1, 
p<0.001) and sex (ΔOFV = -7.4, p=0.007) on CL/F improved significantly the description of the data. In 
contrast, age, ethnicity, smoking status, co-medications and GFR were not associated to varenicline 
pharmacokinetics (ΔOFV > -2.2, p>0.14). Both linear and allometric power functions described 
adequately the relationship between CL/F and BW (ΔOFV ≤ -14.5). According to the AIC, the allometric 
power function was chosen to depict the BW impact on CL/F (AIC= 242 and AIC= 240 for the allometric 
and linear relationships, respectively).  
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Among all tested genetic covariates, only UGT2B7 rs7439366 (ΔOFV = -9.0, p=0.003) and NR1|2 
rs1523130 (ΔOFV = -5.6, p=0.02) showed an influence on varenicline CL/F. No statistical significant 
differences in CL/F between UGT2B7 rs7439366 Hom-Alt and Het-Alt individuals as well as between 
NR1|2 rs1523130 Hom-Alt and Het-Alt individuals were observed compared to the rich model (ΔOFV 
> -0.03, p>0.87). A CL/F of 8.5 L/h was estimated for UGT2B7 rs7439366 Hom-Alt and Het-Alt subjects 
and increased to 10.3 L/h for Ref individuals. NR1|2 rs1523130 Hom-Alt and Het-Alt individuals were 
found to have a CL/F of 9.8 L/h, which decreased to 7.4 L/h for Ref subjects. 
Multivariate analyses revealed that height and sex were correlated to BW, which was thus identified 
as the only significant non-genetic covariate influencing varenicline elimination. The inclusion of the 
UGT2B7 rs7439366 polymorphism on CL/F further improved the description of the data (ΔOFV = -6.4, 
p=0.01). On the other hand NR1|2 rs1523130 did not remain statistically significant (ΔOFV = 1.5, 
p=0.22). Our final results suggest that CL/F is increased by 46% in 100-kg individuals compared to 60-
kg individuals and by 21% in UGT2B7 rs7439366 Ref individuals with respect to Hom-Alt and Het-Alt 
individuals. BW and the UGT2B7 rs7439366 polymorphism explained 14% and 9% of the inter-
individual variability in CL/F, respectively. 
Of 2000 replicates analyzed during the bootstrap analysis of the pharmacokinetic model, 1% failed to 
minimize successfully and were excluded. The bootstrap and the final model results are presented in 
Table 2. The model was considered reliable since the parameter estimates differed less than 10% from 
the bootstrap medians and lied within the bootstrap 95%CI. NPDE distribution was not found to be 
significantly different from a normal distribution and the goodness-of-fit plots were satisfactory 
meaning that the model adequately described the observed data (Supplemental Figure 1 and 2). The 
VPC of the observed dose-normalized concentrations versus time from the beginning of the treatment 
is shown in Figure 1 and the prediction- and variability-corrected VPC of the concentrations versus 
time after dose is shown in Supplemental Figure 3.  
Major differences in varenicline exposure were observed with regard to BW and UGT2B7 rs7439366 
polymorphism in Figure 2. In patients with high BW, 31% and 72% of Ref and Hom-Alt/Het-Alt 
individuals, respectively are under the targeted range. Patients with very low BW and especially Hom-
Alt/Het-Alt individuals are over the targeted range.  
Exposure-response analysis 
The basal turnover model fitted the data correctly. The A parameter estimate was 5.8 ppm/d and the 
EFFCPD parameter 1.9 ppm/d, meaning that for one more cigarette smoked during the day, Kin is 
increased by 1.9 ppm. Kout could not be estimated and was thus fixed to 2.77 day-1 to achieve a CO 
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mean half-life of 6 hours [44]. Residual variability was described by an additive error model and 
estimated to 2.3 ppm. The inter-individual variability of the input rate Kin (IIV Kin) was 46%. All the 
parameters were correctly estimated (relative standard error, RSE< 15%). 
Univariate analysis showed that sex (ΔOFV = -11.3, p<0.001), score of insomnia (∆OFV=-15.7, p<0.001), 
score of depression (∆OFV=-6.1, p=0.01) and score of irritation (∆OFV=-5.4, p=0.02) had a significant 
impact on the EFFCPD parameter. All remaining covariates were not improving the basal model (∆OFV 
> -3.70, p=0.054).  
Multivariate analysis did not discard any of the identified influential covariates on EFFCPD (∆OFV > 7.7, 
p=0.006). The model suggested a decrease in EFFCPD of 63% in female compared to male individuals, 
an increase in EFFCPD of 154% in individuals with the highest score on insomnia (15) compared to the 
lowest score (3), an increase of 96% in individuals with the highest score of depression (20) compared 
to the lowest score (4) and a decrease of 62% in individuals with the highest score of irritation (20) 
compared to the lowest score (4) (see Supplemental Table 1). The effects of sex, score of insomnia, 
depression and irritation were correctly estimated (RSE = 8%, 24%, 39% and 12%, respectively). The 
final model results are presented in Supplemental Table 1. 
Of 2000 replicates analyzed during the bootstrap analysis of the exposure-response model, 1% failed 
to minimize successfully and were excluded. The parameter estimates of A, IIV Kin and the residual 
error differed less than 10% from the bootstrap medians and lied within the bootstrap 95%CI. 
However, the estimates of EFFCPD and of the effects of the sex, score of insomnia, depression and 
irritation differed more than 16% from the bootstrap medians. 95% CI of the bootstrap medians for 
the effect of the sex and the three scores were not significant.  
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DISCUSSION 
This work presents the exposure to varenicline in a real setting of patients enrolled in a clinical and 
pharmacogenetic study. The pharmacokinetics of varenicline are in good accordance with reported 
values. The CL/F estimate for a 70-kg individual with normal creatinine clearance was 8.5 L/h 
(95%CI=7.9-9.2) in Hom-Alt/Het-Alt individuals and increased by 21% in Ref individuals (10.3 L/h, 
95%CI=8.5-12.2). This range is in accordance with the clearance reported for a 70-kg individual with a 
creatinine clearance of 100 mL/min (10.4 L/h, 95%CI=10.2-10.6) [15]. The V/F estimated in the present 
study (228 L, 95%CI=192-275) was significantly lower than the steady-state volume of distribution 
published for a two-compartment model (Vss=415 L, 95%CI=371-463) and so was our estimation of 
the elimination half-life (19h vs 24h). Since 95% of the drug concentrations available in our study 
population were collected less than 12 hours after dose administration, the characterization of the 
profound compartment could not be done. Nevertheless, it is in agreement with the central volume 
estimated in adolescents by a one-compartment model (V =215 L, 95%CI=204-238) [45]. Only 10% of 
the study population had a mildly reduced kidney function (defined as GFR estimated with MDRD 
formula < 90 mL/min). The absence of subjects with severe impaired renal function might explain the 
absence of effect of this variable on varenicline elimination, previously described in adults [15]. The IIV 
CL/F (26%) estimated in the base one-compartment model was found to be explained in part by the 
BW and the genetic polymorphism of UGT2B7 rs7439366 resulting in a decreased of IIV CL/F to 19% 
close to the reported value of 25% [15].  
The originality of our work is in the analysis of the influence of genetic factors (i.e. OCT2, UGT2B7 and 
nuclear factors) on varenicline clearance. UGT2B7 rs7439366 Hom-Alt/Het-Alt individuals had a 
decrease of varenicline clearance compared to Ref subjects. This is in accordance with a reported 
reduced morphine-6-glucuronide/morphine ratio in Hom-Alt individuals compared to Ref individuals 
in a study involving 86 patients [46] although contradictory results have been published [47,48]. Of 
note, it has been showed that PXR is not involved in UGT2B7 expression [49,50] but could regulate the 
OCT2 expression as suggested in rats [51]. 
Despite the weak proportion of variability in the varenicline concentrations separately explained by 
BW (14%) or UGT2B7 rs7439366 polymorphism (9%), Figure 2 highlighted a 4-times variation in 
varenicline exposure between the two extreme groups of BW and UGT2B7 rs7439366 polymorphism 
(CminSS = 12 ng/mL and 3.4 ng/mL in the group of 45 kg/Hom-Alt/Het-Alt and 130 kg/Ref individuals, 
respectively). The variation in varenicline exposure decreased to 2.6 if only the two extreme groups of 
BW are considered (CminSS = 12 ng/mL and 4.6 ng/mL in the group of 45 kg and 130 kg with the same 
UGT2B7 rs7439366 genotype, respectively). Moreover, a positive association between varenicline 
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exposure and probability of abstinence or nausea incidence has been shown at the dose 1 mg b.i.d [3]. 
Subjects with very low BW and especially the Hom-Alt/Het-Alt subjects are overexposed to varenicline 
and nausea could be more frequent and could affect the patient adherence to the treatment. In 
contrary, overweight smokers and Ref individuals in particular might have a lower probability of 
abstinence at this dose due to underexposition to the drug. Thus, dose adjustment according to BW 
values and UGT2B7 genotype if known should be considered to maximize the probability of abstinence 
while limiting the apparition of nausea, the most prevalent side-effect of varenicline. For overweight 
subjects and especially UGT2B7 Ref individuals, this work suggests to increase the dose as it has been 
already proposed for nonresponders to the standard dose in a clinical experience [52]. We 
acknowledge that in the present study the effect of UGT2B7 rs7439366 polymorphism observed on 
varenicline concentrations is more important than expected based on the data published by Obach et 
al. [4]. It is indeed reported that varenicline N-carbamoylglucuronide represent in excreta 3.6% of the 
dose but the study included only 6 subjects with unknown metabolizer status for UGT2B7. In the 
present study, the genotypes UGT2B7 rs7439366 CC/TC corresponded to the majority of the study 
sample (77%, table 1) which is in good agreement with the reported genotype distribution in the 
European population and excluded a selection bias  [53]. In the present study, the effect of UGT2B7 
rs7439366 polymorphism on varenicline pharmacokinetics is of limited clinical relevance and however 
lower than the body weight effect. 
In this study, the exposure-response analysis did not show any influence of varenicline concentrations 
on CO levels contrary to the study from Ravva et al. [3]. Here, most of the patients (92%) were abstinent 
(expired CO measurements below 10 ppm) thus preventing the estimation of any positive relationship 
between varenicline exposure and abstinence. In contrast in the study from Ravva et al. positive 
relationship was characterized in a study population with almost 50% of abstinent individuals. The 
bootstrap analysis revealed that the effect of the covariates were not statistically significant possibly 
due to the right-skewed distribution of the covariates in our analyzed population.  
Limitations of the present work should be noted. First, the limited amount of pharmacokinetic data in 
early and late times after dose prevented the estimation of the absorption constant and of the second 
volume of distribution of varenicline, respectively. A second major limitation of the work resides in the 
assumption that the participants had good adherence to the treatment and that all doses were taken 
by the participants. It must be mentioned that, although adherence cannot be ascertained, all 
participants were asked about the actual intake of varenicline at each visit. Third, in this analyzed 
population most of the participants were abstinent after a 3-month treatment period. 
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Despite these limitations, our study is the first to analyze the genetically-based variability of varenicline 
pharmacokinetic. This work showed that UGT2B7 polymorphism and BW can influence varenicline 
concentrations. During smoking cessation program, in case of lack of abstinence in overweight 
individuals or apparition of side-effects in underweight individuals, dose adjustment based on BW and, 
if available, on UGT2B7 genotype, might be useful to improve clinical efficacy and tolerability of 
varenicline. 
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